They introduced IL‐17 and TGF‐β as targets for the immunotherapy of advanced stage BC (Baharlou, Ahmadi Vasmehjani, Dehghani, Ghobadifar, & Khoubyari, 2014). Here, TGFB1 is linked to breast cancer.